Expect negative price reaction for BIIB and DNLI on the trial failure and discontinuation. Monitor for any further pipeline updates or strategic shifts from Biogen. Denali's independent BEACON study in LRRK2 carriers may provide partial offset.
BIIB drugs
BIIB drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 22 $193.85entry
- T+1 · 6mo ago −0.40%α −0.99% · $193.07
- T+5 · 6mo ago −0.84%α −2.50% · $192.22
- T+20 · 5mo ago +3.02%α +3.19% · $199.71
- T+60 · 3mo ago +9.21%α +6.28% · $211.70
Price Chart
How similar events traded
Executive Summary
Biogen and Denali announced that the Phase 2b LUMA study of BIIB122 in early-stage Parkinson's disease failed to meet its primary and secondary endpoints. Development of BIIB122 for idiopathic Parkinson's disease will be discontinued, a significant setback for Biogen's pipeline.
Key Facts
- Phase 2b LUMA study of BIIB122 did not meet primary endpoint of Time to Confirmed Worsening in MDS-UPDRS Part II and III combined score.
- Secondary endpoints also did not show benefit with BIIB122.
- Biogen and Denali will discontinue further development of BIIB122 in idiopathic Parkinson's disease.
- Denali continues Phase 2a BEACON study in LRRK2 variant carriers independently.
- BIIB122 was generally well tolerated with >90% kinase inhibition achieved.
Financial Impact
Development costs and potential write-offs for BIIB122, but no specific dollar amounts disclosed in the press release.
Risk Factors
- Loss of potential revenue from BIIB122 in idiopathic Parkinson's disease.
- Reduced investor confidence in Biogen's pipeline efficiency.
- Potential impairment of collaboration assets.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3299820 |
Track record
34 reports on BIIB
10 of 11 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jul 13, 2026 report. 15 of 16 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Neutral 3/10 Entry $253.40 Now $251.65 −0.69% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $253.25 Now $251.65 −0.63% settles Feb 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $254.87 Now $251.65 −1.26% settles Feb 5
- Oct 28, 202619d ago Institutional Cluster Neutral 2/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
- Oct 28, 202619d ago 8-K Bullish 6/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
- Oct 19, 202628d ago Press Release Neutral 4/10 Entry $233.48 Now $251.65 +7.78% settles Jan 14
- Oct 12, 20265w ago ANALYST-UPGRADE Bullish 6/10 Entry $229.41 Now $251.65 +9.69% settles Jan 7
- Oct 2, 20266w ago Press Release Bullish 6/10 Entry $219.88 Now $251.65 +14.45% settles Dec 29
- Sep 17, 20268w ago Press Release Bullish 5/10 Entry $215.50 Now $251.65 +16.77% settles Dec 14
- Sep 3, 202610w ago Press Release Neutral 4/10 Entry $220.83 Now $251.65 +13.96% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers